Recent News

• 10.16.2026 - Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors
• 08.13.2026 - Curis, Inc. Announces Pricing of $5.6 Million Public Offering
• 07.30.2026 - Curis Doses First Five Patients in TakeAim CLL Study
• 07.22.2026 - Curis Announces Positive Emavusertib Update
• 07.06.2026 - Curis Consents First Six Patients in TakeAim CLL Study
• 07.02.2026 - Molecular Cancer Therapeutics: Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib
• 06.26.2026 - Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
• 05.12.2026 - Curis Provides First Quarter 2026 Business Update
• 05.05.2026 - Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
• 04.04.2026 - Washington University School of Medicine

Recent Filings

• 08.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2026 - 424B4 Prospectus [Rule 424(b)(4)]
• 08.12.2026 - EFFECT Notice of Effectiveness
• 08.10.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 07.30.2026 - 8-K Current report
• 07.17.2026 - DRS Draft Registration Statement
• 07.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.09.2026 - 4 Statement of changes in beneficial ownership of securities